Celldex Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Celldex Therapeutics's estimated annual revenue is currently $15M per year.
- Celldex Therapeutics's estimated revenue per employee is $82,873
- Celldex Therapeutics's total funding is $875M.
Employee Data
- Celldex Therapeutics has 181 Employees.
- Celldex Therapeutics grew their employee count by 7% last year.
Celldex Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr VP and Chief Medical Officer | Reveal Email/Phone |
2 | VP, Research | Reveal Email/Phone |
3 | VP, Preclinical R&D and Bioanalytics | Reveal Email/Phone |
4 | VP, Clinical Science | Reveal Email/Phone |
5 | VP, Manufacturing Operations and Supply at Celldex Therapeutics | Reveal Email/Phone |
6 | VP Project Management | Reveal Email/Phone |
7 | SVP & CFO | Reveal Email/Phone |
8 | SVP, Corporate Affairs & Administration | Reveal Email/Phone |
9 | SVP and Chief Business Officer | Reveal Email/Phone |
10 | Senior Director Human Resources | Reveal Email/Phone |
Celldex Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is Celldex Therapeutics?
Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious diseases and immune system disorders through our novel 'active immunization' approach. We have developed our Antigen Presenting Cell Targeting Technology (APC Targeting Technology™) that utilizes proprietary human monoclonal antibodies to directly target specialized types of immune system cells known as antigen presenting cells, or APCs - particularly dendritic cells. We are using this technology approach to build a substantial pipeline of clinical development candidates that will address significant gaps in the treatment of many specific cancers, as well as within our growing activities in infectious disease and auto-immune disorders
keywords:N/A
$875M
Total Funding
181
Number of Employees
$15M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Celldex Therapeutics News
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment...
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment...
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment...
HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the of ...
Gerald McMahon, CEO, Kolltan Eight months after watching expectations for its cancer vaccine Rintega (rindopepimut) implode in a failed Phase III glioblastoma study, Celldex Therapeutics $CLDX is doing some pipeline reconstruction, buying out Kolltan Pharmaceuticals i ...
Other Companies in Hampton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 189 | 7% | N/A |
#2 | $65.1M | 194 | N/A | N/A |
#3 | $41.2M | 208 | 16% | N/A |
#4 | $15M | 217 | 1% | N/A |
#5 | $75.6M | 223 | -7% | N/A |